InsiderTrades

Form 4 for CYTK CYTOKINETICS INC

Accepted 2026-03-05 00:00:00 ET · period of report 2026-03-05 · accession 0001061983-26-000015 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-03-05 2026-03-05 CYTK Callos Andrew EVP, Chief Commercial Off M - OptEx $29.97 +26.0K 76.4K +52% +$779.3K
DM 2026-03-05 2026-03-05 CYTK Callos Andrew EVP, Chief Commercial Off S - Sale+OE $61.87 -26.0K 61.4K -30% -$1.61M
DM 2026-03-05 2026-03-05 CYTK Callos Andrew EVP, Chief Commercial Off M - OptEx $0.00 -26.0K 24.4K -52% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-05 M A 15,000 $23.26 65,440 D — —
2 Common Common Stock 2026-03-05 S D 11,000 $61.88 50,440 D — —
3 Common Common Stock 2026-03-05 M A 11,000 $39.13 76,440 D — —
4 Common Common Stock 2026-03-05 S D 15,000 $61.87 61,440 D — —
5 Derivative Non-Qualified Stock Option (Right to Buy) 2026-03-05 M D 15,000 $0.00 69,000 D $23.26 · 2022-03-31 to 2031-03-31 15,000 Common Stock (F1) Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
6 Derivative Non-Qualified Stock Option (Right to Buy) 2026-03-05 M D 11,000 $0.00 24,403 D $39.13 · 2023-04-06 to 2033-03-06 11,000 Common Stock